[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nmdar-autoimmune-encephalitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nmdar-autoimmune-encephalitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100605108","long-term-impact-of-nmdar-encephalitis-level-3-100605108",false,"NCT07158229","Long-term Impact of NMDAR Encephalitis, Level 3","Social and Psychological Long-term Impact of NMDA Receptor Encephalitis, Level 3","SAPIENCE 3","Inclusion Criteria:\n\n* Patients with NMDAR encephalitis\n* Age ≥ 18 years old\n* Patient affiliated to a social security system\n* No opposition from the patient\n* Access to an internet connection and a computer\n\nExclusion Criteria:\n\n* Patients whithout NMDAR encephalitis\n* Patient under guardianship or curatorship\n* Patient with neurological disorders pre-existing encephalitis","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored.\n\nCurrently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.",[25],"NMDAR Autoimmune Encephalitis",[27,28],"NMDAR encephalitis","psychosocial impact","RECRUITING","2026-02-12",{"date":32,"type":33},"2026-02-17","ACTUAL",{"date":35,"type":33},"2025-11-21",{"date":37,"type":21},"2026-11-21",{"name":39,"class":40},"Hospices Civils de Lyon","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100603176","medium-term-effects-of-treatments-in-autoimmune-encephalitis-100603176","NCT07133113","Medium-term Effects of Treatments in Autoimmune Encephalitis","Medium-term Effects of Treatments in Autoimmune Encephalitis (META): a Real-life, Observational Prospective Study","META","Inclusion Criteria:\n\n* Adult or child patient with encephalitis defined as anti-GAD, NMDAR, LGI1, CASPR2, IgLON5 or GFAP\n* Untreated or with a decision to treat within the previous 30 days.\n\nExclusion Criteria:\n\n\\- Refusal by the referring doctor to participate or refusal by the patient mentioned in the objection to the use of his\u002Fher clinical data.",{"count":51,"type":21},200,"Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence. Commonly used treatments are divided into so-called first-line (steroids, intravenous immunoglobulins, plasma exchanges) and second-line (rituximab, cyclophosphamide, tocilizumab, others), and may be used in association or sequentially. There is no standard practice, and initial treatment protocol may consist in first-line alone, first-line with rituximab, or first-line with dual immunosuppression (rituximab and cyclophosphamide). Absence of clear response to initial treatment in the first 4 to 6 weeks may indicate undertreatment and is generally followed by treatment escalation, mostly to dual immunosuppression. However, as the frequency of non-responders to initial treatment is unknown, it is still unclear whether dual immunosuppression should be offered to all patients from inception.",[25,54,55,56,57,58],"LGI1 Antibody Associated Encephalitis","CASPR2-Antibody","IgLON5","GAD65","GFAP",[60,61],"Paraneoplastic neurological disorder","autoimmune encephalitis","2025-08-13",{"date":64,"type":33},"2025-08-20",{"date":66,"type":33},"2024-09-01",{"date":68,"type":21},"2027-03-01",{"name":39,"class":40}]